Andrea Marzi

{{short description|German-American virologist}}

{{Infobox scientist

| name = Andrea Marzi

| alma_mater = University of Erlangen–Nuremberg (PhD)

| nationality = German

| workplaces = National Microbiology Laboratory
Rocky Mountain Laboratories

| fields = Immunobiology, molecular virology

| awards = {{Interlanguage link|Loeffler-Frosch-Medaille|lt=Loeffler-Frosch medal|de||WD=}} (2019)

| image = Andrea Marzi.jpg

| thesis_title = The role of cellular attachment factors for filovirus infection

| thesis_url = https://opus4.kobv.de/opus4-fau/frontdoor/index/index/year/2007/docId/473

| thesis_year = 2007

| doctoral_advisor = {{Interlanguage link|Uwe Sonnewald|lt=|de||WD=}}

}}

Andrea Marzi is a German-American virologist. She is chief of the immunobiology and molecular virology unit at the Rocky Mountain Laboratories. Marzi investigates the pathogenesis of filoviruses and vaccine development. She received the {{Interlanguage link|Loeffler-Frosch-Medaille|lt=Loeffler-Frosch medal|de||WD=}} in recognition of her research.

Education

In 2007, Marzi received a Ph.D. in virology from the University of Erlangen–Nuremberg where she studied the glycoprotein-mediated entry of Ebola virus (EBOV) and HIV. Her doctoral advisor was {{Interlanguage link|Uwe Sonnewald|lt=|de||WD=}}. Her dissertation was titled The role of cellular attachment factors for filovirus infection.{{Cite web|last=Marzi|first=Andrea|title=Die Bedeutung zellulärer Anheftungsfaktoren für die Filovirus-Infektion|url=https://opus4.kobv.de/opus4-fau/frontdoor/index/index/year/2007/docId/473|language=en|access-date=2020-03-29}} Later that year, Marzi moved to Winnipeg to join Heinz Feldmann’s group at the National Microbiology Laboratory to work in the Biological Safety Level 4 (BSL4) on filoviruses and EBOV vaccines.{{Cite web|url=https://www.niaid.nih.gov/research/andrea-marzi|title=Andrea Marzi, Ph.D. NIH: National Institute of Allergy and Infectious Diseases|website=www.niaid.nih.gov|access-date=2020-03-29}}

Career

In 2008, Marzi moved with Feldmann to the Rocky Mountain Laboratories and continued her BSL4 work on vaccine development for highly pathogenic viruses using primarily the vesicular stomatitis virus (VSV) platform. She also studied the pathogenesis of filoviruses and developed small animal models for these pathogens. Recently, she expanded the VSV vaccine platform to other emerging pathogens like Zika virus. In 2013, Marzi was promoted to staff scientist, and in 2017 to associate scientist. Marzi was selected as a tenure-track investigator in the National Institute of Allergy and Infectious Diseases Laboratory of Virology in 2019. She is chief of the immunobiology and molecular virology unit.

Awards and honors

In 2019, the German Society of Virology recognized Marzi with the {{Interlanguage link|Loeffler-Frosch-Medaille|lt=Loeffler-Frosch medal|de||WD=}} for her research on filoviruses and vaccine development.{{Cite web|url=https://www.dpz.eu/en/unit/infection-biology-unit/infection-biology-unit/news-single-view/news/andrea-marzi-erhaelt-den-loeffler-frosch-preis.html|title=Andrea Marzi receives Loeffler-Frosch-Award|website=Deutsches Primatenzentrum|language=de|access-date=2020-03-29}}

References